Optimization of Cardiac Metabolism in Heart Failure
Open Access
- 1 December 2011
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 17 (35) , 3846-3853
Abstract
The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metabolized. In contrast, glucose becomes an important preferential substrate for metabolism and ATP generation under specific pathological conditions, because it can provide greater efficiency in producing high energy products per oxygen consumed compared to fatty acids. Manipulations that shift energy substrate utilization away from fatty acids toward glucose can improve the cardiac function and slow the progression of heart failure. However, insulin resistance, which is highly prevalent in the heart failure population, impedes this adaptive metabolic shift. Therefore, the acceleration of the glucose metabolism, along with the restoration of insulin sensitivity, would be the ideal metabolic therapy for heart failure. This review discusses the therapeutic potential of modifying substrate utilization to optimize cardiac metabolism in heart failure.Keywords
This publication has 81 references indexed in Scilit:
- Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodentsJournal of Clinical Investigation, 2010
- Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunctionEuropean Heart Journal, 2009
- Akt Increases Sarcoplasmic Reticulum Ca2+ Cycling by Direct Phosphorylation of Phospholamban at Thr17Journal of Biological Chemistry, 2009
- Substrate–Enzyme Competition Attenuates Upregulated Anaplerotic Flux Through Malic Enzyme in Hypertrophied Rat Heart and Restores Triacylglyceride ContentCirculation Research, 2009
- Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 AdipocytesEndocrinology, 2008
- Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathwayAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnoverJournal of Molecular and Cellular Cardiology, 2008
- Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied HeartsCirculation, 2007
- Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failureEuropean Heart Journal, 2006
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJournal of Clinical Investigation, 2005